Karoly Szuhai

Dr. Karoly Szuhai

Leiden University Medical Center, Leiden, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2011 in Science
Verified
Journal Article
Closed access
PDF file
AJAniek Janssen
Aniek Janssen
MBMarja van der Burg
Marja van der Burg
Karoly SzuhaiKaroly Szuhai
Karoly Szuhai
Geert KopsGeert Kops
Geert Kops
RMRené H. Medema
René H. Medema
Altering whole-chromosome number can directly increase chromosome structural damage in cancer cells.

12 October 2006 in Stem Cells
Verified
Journal Article
Open access
PDF file
JTJakub Tolar
Jakub Tolar
ANAlma J. Nauta
Alma J. Nauta
MOMark J. Osborn
Mark J. Osborn
AMAngela Panoskaltsis Mortari
Angela Panoskaltsis Mortari
RMRon T. McElmurry
Ron T. McElmurry
BBBruce R. Blazar
Bruce R. Blazar
To study the biodistribution of MSCs, we labeled adult murine C57BL/6 MSCs with firefly luciferase and DsRed2 fluorescent protein using nonviral Sleeping Beauty transposons and coinfused labeled MSCs with bone marrow into irradiated allogeneic recipients. Using in vivo whole-body imaging, luciferase signals were shown to be increased between weeks 3 and 12. Unexpectedly, some mice with the highest luciferase signals died and all surviving mice developed foci of sarcoma in their lungs. Two mice also developed sarcomas in their extremities. Common cytogenetic abnormalities were identified in tumor cells isolated from different animals. Original MSC cultures not labeled with transposons, as well as independently isolated cultured MSCs, were found to be cytogenetically abnormal. Moreover, primary MSCs derived from the bone marrow of both BALB/c and C57BL/6 mice showed cytogenetic aberrations after several passages in vitro, showing that transformation was not a strain-specific nor rare event. Clonal evolution was observed in vivo, suggesting that the critical transformation event(s) occurred before infusion. Mapping of the transposition insertion sites did not identify an obvious transposon-related genetic abnormality, and p53 was not overexpressed. Infusion of MSC-derived sarcoma cells resulted in malignant lesions in secondary recipients. This new sarcoma cell line, S1, is unique in having a cytogenetic profile similar to human sarcoma and contains bioluminescent and fluorescent genes, making it useful for investigations of cellular biodistribution and tumor response to therapy in vivo. More importantly, our study indicates that sarcoma can evolve from MSC cultures.

6 November 2011 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TPTwinkal C Pansuriya
Twinkal C Pansuriya
RERonald van Eijk
Ronald van Eijk
ADAdamo Pio d'Adamo
Adamo Pio d'Adamo
MRMaayke A J H van Ruler
Maayke A J H van Ruler
Marieke KuijjerMarieke Kuijjer
Marieke Kuijjer
Judith V.M.G. BovéeJudith V.M.G. Bovée
Judith V.M.G. Bovée
Judith Bovée and colleagues report the identification of somatic mosaic mutations in IDH1 and IDH2 in tumors from individuals with Ollier disease and Maffucci syndrome, which are non-hereditary skeletal disorders characterized by multiple enchondromas. Ollier disease and Maffucci syndrome are non-hereditary skeletal disorders characterized by multiple enchondromas (Ollier disease) combined with spindle cell hemangiomas (Maffucci syndrome). We report somatic heterozygous mutations in IDH1 (c.394C>T encoding an R132C substitution and c.395G>A encoding an R132H substitution) or IDH2 (c.516G>C encoding R172S) in 87% of enchondromas (benign cartilage tumors) and in 70% of spindle cell hemangiomas (benign vascular lesions). In total, 35 of 43 (81%) subjects with Ollier disease and 10 of 13 (77%) with Maffucci syndrome carried IDH1 (98%) or IDH2 (2%) mutations in their tumors. Fourteen of 16 subjects had identical mutations in separate lesions. Immunohistochemistry to detect mutant IDH1 R132H protein suggested intraneoplastic and somatic mosaicism. IDH1 mutations in cartilage tumors were associated with hypermethylation and downregulated expression of several genes. Mutations were also found in 40% of solitary central cartilaginous tumors and in four chondrosarcoma cell lines, which will enable functional studies to assess the role of IDH1 and IDH2 mutations in tumor formation.

1 January 2007 in Analytical Cellular Pathology
Verified
Journal Article
Open access
PDF file
WMWilma Mesker
Wilma Mesker
JJJan M. C. Junggeburt
Jan M. C. Junggeburt
Karoly SzuhaiKaroly Szuhai
Karoly Szuhai
PHPieter de Heer
Pieter de Heer
HMHans Morreau
Hans Morreau
RTRob A. E. M. Tollenaar
Rob A. E. M. Tollenaar
Background: Tumor staging insufficiently discriminates between colon cancer patients with poor and better prognosis. We have evaluated, for the primary tumor, if the carcinoma‐percentage (CP), as a derivative from the carcinoma‐stromal ratio, can be applied as a candidate marker to identify patients for adjuvant therapy. Methods: In a retrospective study of 63 patients with colon cancer (stage I–III, 1990–2001) the carcinoma‐percentage of the primary tumor was estimated on routine H&E stained histological sections. Additionally these findings were validated in a second independent study of 59 patients (stage I–III, 1980–1992). (None of the patients had received preoperative chemo‐ or radiation therapy nor adjuvant chemotherapy.) Results: Of 122 analyzed patients 33 (27.0%) had a low CP and 89 (73.0%) a high CP. The analysis of mean survival revealed: overall‐survival (OS) 2.13 years, disease‐free‐ survival (DFS) 1.51 years for CP‐low and OS 7.36 years, DFS 6.89 years for CP‐high. Five‐year survival rates for CP‐low versus CP‐high were respectively for OS: 15.2% and 73.0% and for DFS: 12.1% and 67.4%. High levels of significance were found (OS p < 0.0001, DFS p < 0.0001) with hazard ratio’s of 3.73 and 4.18. In a multivariate Cox regression analysis, CP remained an independent variable when adjusted for either stage or for tumor status and lymph‐node status (OSp < 0.001, OSp < 0.001). Conclusions: The carcinoma‐percentage in primary colon cancer is a factor to discriminate between patients with a poor and a better outcome of disease. This parameter is already available upon routine histological investigation and can, in addition to the TNM classification, be a candidate marker to further stratify into more individual risk groups.

4 January 2011 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
DJDanielle de Jong
Danielle de Jong
SVSofie Lj Verbeke
Sofie Lj Verbeke
DMDanielle Meijer
Danielle Meijer
Pancras C.W. HogendoornPancras C.W. Hogendoorn
Pancras C.W. Hogendoorn
Judith V.M.G. BovéeJudith V.M.G. Bovée
Judith V.M.G. Bovée
Karoly SzuhaiKaroly Szuhai
Karoly Szuhai
Molecular genetic studies on rare tumour entities, such as bone tumours, often require the use of decalcified, formalin-fixed, paraffin-embedded tissue (dFFPE) samples. Regardless of which decalcification procedure is used, this introduces a vast breakdown of DNA that precludes the possibility of further molecular genetic testing. We set out to establish a robust protocol that would overcome these intrinsic hurdles for bone tumour research.

9 July 2009 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
AMAlexander B Mohseny
Alexander B Mohseny
Karoly SzuhaiKaroly Szuhai
Karoly Szuhai
SRSalvatore Romeo
Salvatore Romeo
EBEmilie P Buddingh
Emilie P Buddingh
IBInge Briaire‐De Bruijn
Inge Briaire‐De Bruijn
Pancras C.W. HogendoornPancras C.W. Hogendoorn
Pancras C.W. Hogendoorn